retatrutide and energy Pittsburgh Exploring Retatrutide's Impact on Metabolism

That rise in cyclic AMP is the central second messenger of GLP-1 action, working through protein kinase A and the exchange protein Epac2 to drive the receptors downstream effects

September 16, 2025

Retatrutide is an investigational triple agonist peptide designed to activate GLP-1, GIP and glucagon receptors

Tariq explains, a recommendation bolstered by a recent review

The hope now is that peptide-based therapies could deliver those benefits more precisely

Early clinical trial data from the Phase 2 studies published in the New England Journal of Medicine suggest that retatrutide may indeed have a favourable profile when it comes to body composition